Characteristics | Total | TMEM240 mRNAb | TMEM240 methylation | ||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Low n (%) | High n (%) | Low n(%) | High n(%) | ||||
Overall | 714 | 427 (59.8) | 287 (40.2) | 582 | 351 (60.3) | 231 (39.7) | |||
Age | 761 | Â | Â | Â | Â | Â | Â | Â | Â |
 < 65 | 551 | 331 (60.1) | 220 (39.9) | 453 | 264 (58.3) | 189 (141.7) | |||
 ≥65 | 210 | 127 (60.5) | 83 (39.5) | 170 | 108 (63.5) | 251 (40.3) | |||
Race | 525 | Â | Â | Â | Â | Â | Â | Â | |
 White | 421 | 259 (61.5) | 162 (38.5) | 338 | 234 (69.2) | 104 (30.8) | |||
 Black/African American | 72 | 41 (56.9) | 31 (43.1) | 64 | 19 (29.7) | 45 (70.3) | |||
 Asian | 32 | 27 (84.4) | 5 (15.6)0.022 | 31 | 14 (45.2) | 17 (54.8) <0.001 | |||
Menopause state | 480 | Â | Â | Â | Â | Â | Â | Â | |
 Premenopause | 123 | 76 (61.8) | 47 (38.2) | 103 | 69 (67.0) | 34 (33.0) | |||
 Perimenopause | 16 | 9 (56.3) | 7 (43.8) | 14 | 6 (42.9) | 8 (57.1) | |||
 Postmenopause | 341 | 218 (63.9) | 123 (36.1) | 287 | 174 (60.6) | 113 (39.4) | |||
Histological type | 714 | Â | Â | Â | Â | Â | Â | Â | Â |
 ILC | 170 | 65 (38.2) | 105 (61.8) | 152 | 113 (74.3) | 39 (25.7) | |||
 IDC | 504 | 341 (67.7) | 163 (32.3)<0.001 | 400 | 215 (58.8) | 185 (46.3)<0.001 | |||
 Mucinous carcinoma | 15 | 8 (53.3) | 7 (46.7) | 14 | 11 (78.6) | 3 (21.4) | |||
 Mixed type | 25 | 13 (52.0) | 12 (48.0) | 16 | 12 (75.0) | 4 (25.0) | |||
Tumor stage | 535 | Â | Â | Â | Â | Â | Â | Â | Â |
 I and II | 385 | 247 (64.2) | 138 (35.8) | 311 | 189 (60.8) | 122 (39.2) | |||
 III and IV | 150 | 86 (57.3) | 64 (42.7) | 129 | 80 (62.0) | 49 (38.0) | |||
Tumor Size | 539 | Â | Â | Â | Â | Â | Â | Â | Â |
 T0–T1 | 137 | 93 (67.9) | 44 (32.1) | 114 | 80 (70.2) | 34 (29.8) | |||
 T2–T4 | 402 | 243 (60.4) | 159 (39.6) | 329 | 191 (58.1) | 138 (41.9)0.022 | |||
ER | 535 | Â | Â | Â | Â | Â | Â | Â | Â |
 Negative | 117 | 84 (71.8) | 33 (28.2)0.023 | 103 | 22 (21.4) | 81 (78.6)<0.001 | |||
 Positive | 418 | 252 (60.3) | 166 (39.7) | 340 | 49 (73.2) | 91 (26.8) | |||
PR | 533 | Â | Â | Â | Â | Â | Â | Â | Â |
 Negative | 169 | 118 (69.8) | 51 (30.2)0.020 | 143 | 45 (31.5) | 98 (68.5)<0.001 | |||
 Positive | 364 | 216 (59.3) | 148 (40.7) | 299 | 225 (75.3) | 74 (24.7) | |||
HER2 | 463 | Â | Â | Â | Â | Â | Â | Â | Â |
 Negative | 404 | 245 (60.6) | 159 (39.4) | 340 | 220 (64.7) | 120 (35.3) | |||
 Positive | 59 | 41 (69.5) | 18 (30.5) | 45 | 20 (44.4) | 25 (55.6)0.008 | |||
TNBC | 515 | Â | Â | Â | Â | Â | Â | Â | |
 Yes | 76 | 54 (71.1) | 22 (28.9) | 68 | 13 (19.1) | 55 (80.9)<0.001 | |||
 No | 439 | 267 (60.8) | 172 (39.2) | 358 | 255 (71.2) | 103 (28.8) |